Research output per year
Research output per year
Personal profile
Description of research and teaching
My current work at FIMM is focused on understanding the mechanisms of pathogenesis and drug resistance in hematological malignancies, more specifically in multiple myeloma (MM) and acute myeloid leukemia (AML). This research requires the combination of high throughput drug sensitivity and resistance testing, NGS, and quantitative proteomics. Aims of the work are to identify new treatment strategies for patients with recurrent disease, identify new biomarkers for treatment response, and to develop new methods for patient stratification.
Education/Academic qualification
Biochemistry, Doctor of Philosophy, Faculty of Biological and Environmental Sciences
1 Jan 2009 → 23 Jan 2015
Award Date: 23 Jan 2015
Biochemistry, Master of Science, Faculty of Biological and Environmental Sciences
1 Aug 2003 → 18 Jun 2008
Award Date: 18 Jun 2008
PhD student / Reseach scientist, Institute of Biotechnology
15 Sep 2008 → 30 Apr 2015
Undergraduate student / Research assistant
1 Jun 2003 → 1 Aug 2007
University studies in biology and biochemistry, University of Eastern Finland (UEF)
15 Aug 2000 → 31 Jul 2003
Fields of Science
- 1182 Biochemistry, cell and molecular biology
- Proteomics
- Immunology
- Virology
- 3111 Biomedicine
- Cancer biology
- Personalised cancer medicine
- Haematological malignancies
- Cancer therapy
- Translational research
- 318 Medical biotechnology
- Drug sensitivity and resistance testing
- LC-MS/MS based proteomics
- Flow cytometry
International and National Collaboration
Publications and projects within past five years.
-
CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia
Grey, W., Rio-Machin, A., Casado, P., Gronroos, E., Ali, S., Miettinen, J. J., Bewicke-Copley, F., Parsons, A., Heckman, C. A., Swanton, C., Cutillas, P. R., Gribben, J., Fitzgibbon, J. & Bonnet, D., 22 Jun 2022, In: Science translational medicine. 14, 650, 14 p., 3248.Research output: Contribution to journal › Article › Scientific › peer-review
-
Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
Gebraad, A., Ohlsbom, R., Miettinen, J. J., Emeh, P., Pakarinen, T-K., Manninen, M., Eskelinen, A., Kuismanen, K., Slipicevic, A., Lehmann, F., Nupponen, N. N., Heckman, C. A. & Miettinen, S., May 2022, In: Cells. 11, 9, 22 p., 1574.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
Flanagan, K., Kumari, R., Miettinen, J., Haney, S. L., Varney, M. L., Williams, J. T., Majumder, M. M., Suvela, M., Slipicevic, A., Lehmann, F., Nupponen, N. N., Holstein, S. A. & Heckman, C., Mar 2022, In: Hemasphere. 6, 3, p. e687 9 p., 687.Research output: Contribution to journal › Article › Scientific › peer-review
Open Access -
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
Miettinen, J., Kumari, R., Traustadottir, G. A., Huppunen, M-E. A., Sergeev, P., Majumder, M. M., Schepsky, A., Gudjonsson, T., Lievonen, J., Bazou, D., Dowling, P., O'Gorman, P., Slipicevic, A., Anttila, P., Silvennoinen, R., Nupponen, N. N., Lehmann, F. & Heckman, C., Apr 2021, In: Cancers. 13, 7, 21 p., 1527.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Bolomsky, A., Miettinen, J. J., Malyutina, A., Besse, A., Huber, J., Fellinger, S., Breid, H., Parsons, A., Klavins, K., Hannich, J. T., Kubicek, S., Caers, J., Hübl, W., Schreder, M., Zojer, N., Driessen, C., Tang, J., Besse, L., Heckman, C. & Ludwig, H., 26 Oct 2021, In: Blood advances. 5, 20, p. 4125-4139 15 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open Access
Projects
- 5 Finished
-
Luontaisen immuunivasteen solusignalointiverkostot
Nyman, T., Öhman, T., Söderholm, S., Miettinen, J., Välimäki, E. & Cypryk, W.
01/08/2013 → 31/07/2015
Project: Research project
-
Vakavalle influenssatautimuodolle altistavat geenit ja taudin uudet biologiset merkkiaineet
Nyman, T., Cypryk, W., Öhman, T., Välimäki, E., Söderholm, S., Miettinen, J., Lietzen, N. & Paidikondala, M.
01/01/2012 → 31/12/2014
Project: Research project
-
Luontaisen immuunivasteen solusignalointiverkostot
Nyman, T., Öhman, T., Lietzen, N., Miettinen, J., Söderholm, S., Korolainen, M., Välimäki, E., Cypryk, W. & Paidikondala, M.
01/08/2010 → 31/07/2015
Project: Research project
-
Luontaisen immuunivasteen solusignalointiverkostot
Nyman, T., Öhman, T., Söderholm, S., Välimäki, E., Miettinen, J., Cypryk, W. & Lietzen, N.
01/08/2010 → 31/07/2013
Project: Research project
-
Luontaisen immuunivasteen aktivoitumisen tutkiminen proteomiikan avulla
Halinen, A., Nyman, T., Lietzen, N., Öhman, T., Söderholm, S., Miettinen, J., Välimäki, E., Cypryk, W., Korolainen, M. & Paidikondala, M.
01/01/2010 → 31/12/2014
Project: Research project
Activities
-
24th European Hematology Association (EHA) Congress
Juho Miettinen (Attendee)
13 Jun 2019 → 16 Jun 2019Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars
-
European Hematology Association (External organisation)
Juho Miettinen (Member)
2018 → …Activity: Membership types › Membership or other role in research network
-
23rd European Hematology Association Congress
Juho Miettinen (Attendee)
14 Jun 2018 → 17 Jun 2018Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars
-
Helsinki Hematology Day 2017
Juho Miettinen (Attendee)
16 Feb 2017Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars
-
8th Annual Network Meeting of the Nordic EMBL Partnership for Molecular Medicine: Main Meeting
Juho Miettinen (Attendee)
6 Sep 2017 → 7 Sep 2017Activity: Participating in or organising an event types › Organisation and participation in conferences, workshops, courses, seminars